# United States Patent [19]

Smith et al.

**Patent Number:** [11]

5,863,927

**Date of Patent:** 

Jan. 26, 1999

### [54] DEXTROMETHORPHAN AND AN OXIDASE INHIBITOR FOR TREATING INTRACTABLE CONDITIONS

[75] Inventors: Richard Alan Smith, La Jolla; Jonathan M. Licht, San Diego, both of

Calif.

[73] Assignee: Center for Neurologic Study, La Jolla,

[21] Appl. No.:

464,792

[22] PCT Filed:

Sep. 22, 1994

[86] PCT No.:

PCT/US94/10771

§ 371 Date:

Sep. 19, 1996

§ 102(e) Date: Sep. 19, 1996

[87] PCT Pub. No.: WO96/09044

PCT Pub. Date: Mar. 28, 1996

[51] Int. Cl.<sup>6</sup> ...... A61K 31/44; A61K 31/265; A61K 31/135

**U.S. Cl.** ...... **514/289**; 514/305; 514/491; 514/649; 514/651; 514/652; 514/654

Field of Search ......

..... 514/289, 305, 514/491, 652, 654, 649, 651

[56]

#### References Cited

## U.S. PATENT DOCUMENTS

4,316,888	2/1982	Nelson	424/127
5,166,207		Smith	
5,206,248	4/1993	Smith	514/289 C
5,350,756	9/1994	Smith	514/2890
		Mayer et al	
5,366,980	11/1994	Smith	514/289
5,502,058	3/1996	Mayer et al	514/289
		•	

#### OTHER PUBLICATIONS

Dickenson, A.H., "A cure for wind up: NMDA receptor antagonists as potential analgesics," Trends in Pharm. Sci. 11: 307-309 (1990).

Dickenson, A.H., et al, "Dextromethorphan and levorphanol on dorsal horn nociceptive neurones in the rat," Neuropharmacology 30: 1303-1308 (1991).

France, C.P., et al. "Analgesic Effects of Phencyclidine-Like Drugs in Rhesus Monkeys," J. Pharmacol. Exp. Therapeutics 250: 197-201 (1989).

Mao, J., et al, "Intrathecal treatment with dextrorphan or ketamine potently reduces pain-related behaviors in a rat model of peripheral mononeuropathy," Brain Research 605: 164-168 (1993).

McCarthy, J.P., "Some less familiar drugs of abuse," Med. J. Australia 1971 (2): 1078-1081 (1971).

McQuay, H.J., et al, "Dextromethorphan for the treatment of neurophatic pain: a double-blind randomised controlled crossover trial with integral n-of-1 design," Pain 59: 127-133 (1994).

Tortella, F.C., et al, "Dextromethorphan and neuromodulation: old drug coughs up new activities," Trends in Pharm. Sci. 10: 501-507 (1989).

Zhang et al., "Dextromethorphan: Enhancing its Systemic Availability by Way of Low-dose Quinidine-mediated Inhibition of Cytochrome P4502D6," Clin. Pharm. ? Ther. 51(6) :647-655 (1992).

Primary Examiner-Phyllis G. Spivack Attorney, Agent, or Firm-Patrick D. Kelly, Christine M. Bellas

[57] **ABSTRACT** 

A Methods are disclosed for increasing the effectiveness of dextromethorphan in treating chronic or intractable pain, for treating tinnitus and for treating sexual dysfunction comprising administering dextromethorphan in combination with a therapeutically effective dosage of a debrisoquin hydroxylase inhibitor. A preferred combination is dextromethorphan and the oxidative inhibitor quinidine.

22 Claims, 1 Drawing Sheet

